Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder
Launched by AUVA TRAUMAZENTRUM VIENNA SITE UKH MEIDLING · Dec 22, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a single dose of an anti-osteoporotic drug called zoledronic acid can help improve healing after surgery for chronic rotator cuff tears in the shoulder. The trial aims to find out if this treatment can make a difference in recovery compared to a control group that will not receive the drug. Participants will undergo arthroscopic surgery to repair their rotator cuff and will also be involved in a specific physiotherapy program after the surgery.
To be eligible for this study, participants need to be between 50 and 70 years old and have a confirmed rotator cuff tear that is no larger than 3 centimeters. They must also be willing to follow the physiotherapy plan for four weeks after surgery. It’s important to note that certain conditions, such as pregnancy, diabetes, or previous shoulder surgeries, may exclude someone from participating. If you join the study, you will be contributing to important research that could help improve recovery options for future patients with similar shoulder injuries.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Age between 50 and 70 years
- • Magnetic resonance imaging verified rotator cuff tear (within 6 month prior to surgery)
- • Rupture size with a maximum diameter of 3 cm
- • Willingness to participate in the study
- • Willingness to participate in a unified physiotherapy with use of a shoulder abduction pad for four weeks postoperativel
- Exclusion Criteria:
- • Patients younger than 50 or older than 70 years of age
- • Pregnancy
- • Known allergy to zoledronic acid or other components of the medicinal product
- • Previous fracture of the affected shoulder
- • Previous surgery of the affected shoulder
- • Previous or existing bacterial infection of the affected shoulder
- • Rupture of more than two tendons in the affected shoulder (massive rotator cuff tear)
- • Isolated subscapularis tendon tear
- • Presence of glenohumeral osteoarthritis (Hamada type 3 or higher)
- • Diabetes mellitus (fasting glucose ≥ 126 mg/dl, HbA1C ≥ ZORRO Version Draft1.0/09.05.2022 Page 6 of 42 6.5%)
- • Malignant tumor disease
- • Pathological dental status
- • Known disease that interferes with bone metabolism
- • Concomitant diseases that do not permit general anesthesia
- • Previous therapy with anti-osteoporotic drugs (bisphosphonates, denosumab, teriparatide)
- • Epilepsy
- • Claustrophobia
- • Chronic alcohol abuse
- • Drug abuse
About Auva Traumazentrum Vienna Site Ukh Meidling
Auva Traumazentrum Vienna, located at UKH Meidling, is a leading clinical trial sponsor specializing in trauma care and rehabilitation. Committed to advancing medical research, the center focuses on innovative treatment methodologies and evidence-based practices to improve patient outcomes in trauma management. With a multidisciplinary team of experts and state-of-the-art facilities, Auva Traumazentrum Vienna actively collaborates with research institutions and healthcare professionals to conduct rigorous clinical trials, ensuring the highest standards of safety and efficacy in their studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Jakob Schanda, DDr.
Principal Investigator
AUVA Traumazentrum Vienna Site UKH Meidling
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials